Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prevalence rates of various side effects were studied comparatively among 3 oral contraceptive preparations containing 50 mcg of the estrogen component. Norinyl 1/50, Ovral, and Norlestrin 1 were each randomly assigned to groups of 160 healthy women who had consented to participate in the study designed to quantitate probabilities of experiencing specific side effects and of their continuing into the subsequent cycles. Acne, breast discomfort, nausea, abdominal bloating, headache, fatigue, depression, irritability, vaginal discharge, and breakthrough bleeding were the specific side effects studied; only breakthrough bleedings showed a statistical difference in prevalence. The rate of breakthrough bleeding associated with Ovral use in the 1st 3 cycles (16.6%) was significantly (P .05) lower than that associated with using either Norinyl or Norlestrin (46% and 51.7%, respectively). Norelestrin, aside from breakthrough bleeding, was reported as generally freer of side effects than the other 2 preparations. The probabilities of side effects being experienced in the 2nd or 3rd cycle after the effect(s) was experienced in the 1st cycle showed that overall, for all 3 combination pills, the probabilities significantly decreased from the 2nd to the 3rd cycle (P .05). Also examined was the probability that a side effect would occur in the 2nd or 3rd cycle if the user had not experienced such an effect in the 1st cycle. In each instance, the probabilities are significantly lower (P .05) than the corresponding probabilities where the symptom had been experienced in a previous cycle. These data support the contention that side effects experienced on inititation of oral contraceptives should not prohibit its continuation because the majority of symptoms will disappear as the patient becomes accustomed to the hormonal preparation.
 ...
PMID:The probability of side effects with ovral, norinyl 1/50 and norlestrin. 16 Aug 60

The efficacy of a new contraceptive delayed-action preparation, Deposiston is reviewed. Deposiston is the estrogen-progestin preparation with predominant estrogen activity. The estrogen and progestin eomponents of the preparation are ehtinyl estradiol and norethindrone acetate, respectively. Contraceptive effect is associated with gonadotropic stimulation by estrogen component, while progestin component provides the thermogenic effect. Mutagenicity, carcinogenicity, and toxicity tests show safety of Deposiston. Clinical trials of Deposiston in 815 women over the period of 16,207 cycles (18.1 cycles/woman) confirm contraceptive efficacy of the preparation: pregnancy occurred in only 12 women. Side effects of Deposiston include nausea (16.06%), vomiting (3.7%), headache (5.08%), and vaginal discharge (11.86%). Each Deposiston package contains 3 white estrogen tablets and 2 red progestin tablets. A woman starts to take Deposiston on day 4 of the cycle: white tablets are taken on days 4, 11, and 18 and 2 red tablets are taken on day 25. On day 2-7 after the red progestin tablets, the woman experiences hemorrhage. Average duration of and the amount of blood loss during the hemorrhage do not differ from those during the normal menstruation. Deposiston is indicated for women with recurrent uterine hemorrhages, gastrointestinal disorders, and decreased libido. The preparation is contraindicated for adolescents younger than 16 years of age, for women with hormonal active tumors, thromboembolism, chronic liver diseases, and idiopathic jaundice.
 ...
PMID:[Hormonal contraception using the oral depot preparation, Deposiston]. 35 70

A pilot study was conducted to determine the differences in frequency of physical complaints between 179 Black patients (112 oral contraceptive (OC) users and 67 IUD users) with sickle cell trait (AS) and those without AS. 6 physical complaint types were analyzed: dysmenorrhea; mental depression; vaginal discharge; fatigue; headaches; and nausea-vomiting. Out of 5690 Black patients with hemoglobin AA, 112 OC users and 67 IUD patients with similar age and parity were randomly selected to serve as controls. Cumulative complaint rates (CCR) were measured in comparing the experiences of AS and control patients in the 6 complaint categories. No significant differences between AS and control CCRs at level .05 for any of the 6 complaints were observed for both the OC and IUD groups. For OC users, AS patients reported higher CCR's than control patients for cramps and mental depression while for IUD users, AS patients had higher CCR's for mental depression. The relationship between OCs and mental depression is not clear yet, and further research would benefit AS patients. Another major concern for OC users is the possible development of hypercoagulable state with resultant thromboembolism. Also, evidence suggests that crisis, splenic infarction, and hematuria can develop in AS patients under special conditions; the role of OCs in enhancing the infarctive process in AS patients is not known and needs to be studied further. Further clinical research should also be done to determine the effect of contraception on dysmenorrhea and mental depression in AS patients. AS patients should be observed regularly.
 ...
PMID:Physical complaints of patients with sickle cell trait. 112 75

Toremifene is an antiestrogen that binds strongly to estrogen receptors (ER). A total of 19 previously treated postmenopausal women with metastatic breast cancer whose performance status was good and whose ER status was positive or unknown were studied to determine the maximum tolerated dose of toremifene. Cohorts of patients received 200, 300, or 400 mg/m2 p.o. daily until relapse or unacceptable toxicity had occurred. Nausea, vomiting, and dizziness were dose-related. Three of five patients receiving 400 mg/m2 experienced moderate or severe vomiting and another developed reversible disorientation and hallucinations. Mild sweating, peripheral edema, vaginal discharge, and hot flushes were encountered at all doses. Reversible corneal pigmentation was identified in seven cases but was not of clinical importance. The pharmacokinetics of toremifene was studied weekly and in detail on day 42 using a high-performance liquid chromatographic (HPLC) assay that identified the parent compound and three active metabolites, N-desmethyltoremifene, (deaminohydroxy)toremifene, and didemethyltoremifene. Steady state was achieved at 1-3 weeks. The toremifene area under the curve and the maximal concentration were dose-dependent at high doses. The recommended phase II dose is 300 mg/m2 p.o. daily.
 ...
PMID:Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. 138 61

Seventy-five female patients suffering from advanced breast cancer were treated with toilet mastectomy, radiotherapy and oophorectomy (if premenopausal) or tamoxifen therapy (if postmenopausal) as well as chemotherapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. The most common side-effects of combined chemohormonal therapy were gastro-intestinal (nausea, vomiting, rarely diarrhoea) in 43 patients (57.3%), followed by alopecia in 23 patients (30.6%), myelosuppression in 12 patients (16%), extravasation and thrombophlebitis in 7 patients (9.3%), and mucositis and oral erythema in 3 patients (4%). Side-effects of tamoxifen therapy such as vaginal discharge, bleeding, hot flushes were encountered in 10 patients (13.3%). Hypercalcaemia, tumour flare and hepatic, renal, cardiac, pulmonary and neurological toxicities were not encountered. Improvement of 10-30% in Karnofsky performance status was noted in responders while 20-30% deterioration was observed in non-responders. Combination therapy was mostly well tolerated, side-effects were few and toxicities were temporary and reversible.
 ...
PMID:Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer. 158 18

A comparison of the triphasic Triphasil and the combined oral contraceptive Diane 50 for treatment of acne for 6 cycles showed significant improvement in both groups. Triphasil (Wyeth-Ayerst) contains 50 mcg levonorgestrel and 30 mcg ethinyl estradiol, 75 mcg levonorgestrel and 40 mcg ethinyl estradiol for 5 days and 125 mcg levonorgestrel and 30 mcg ethinyl estradiol for 10 days. Diane 50 (Schering Ag) contains 2 mg cyproterone acetate and 50 mcg ethinyl estradiol for 21 days per cycle. 10 women in each group had physical, pelvic, ophthalmologic and neurologic exams, hematologic and biochemical screens, assays of free testosterone, sex hormone binding globulin (SHBG), androstenedione, dehydroepiandrosterone SO4 (DHEAS), progesterone, and computations of acne and hirsutism scores. Subjects had used tetracyclines, isotretinoin, erythromycin, topical clindamycin and benzoyl peroxide previously, but were withdrawn from medication in the cycle before the intervention. The mean acne scores, derived from grading and counting lesions and comedones, fell from 63.3 to 6 in the Diane 50 and from 64.2 to 4.5 in the Triphasil group. Subjective results were excellent for 6, good for 2 and unsatisfactory for 2 in the Diane 50 group, and excellent for 8 and good for 2 in the Triphasil group. In both groups mean free testosterone, androgen index, androstenedione and DHEAS, and an increase in SHBG were documented. 5 Triphasil and 5 Diane 50 subjects had increased cholesterol levels during the trial, the only abnormality detected. Side effects reported were recurrence of varicose veins and hemorrhoids in 1 women who withdrew, and complaints of mastalgia, nausea, dysmenorrhea, migraine, headache, backache and vaginal discharge.
 ...
PMID:An open study of Triphasil and Diane 50 in the treatment of acne. 183 45

Special side effects which relate to specific areas are discussed. Head and neck radiation produces acute problems related to swallowing, dry mouth, sore throat and thickened saliva which all require medication. Alteration of taste may last for months after radiation is completed. Radiation to lungs may cause worsening breathlessness and coughing which may necessitate interruption of treatment. Radiation to pelvis and abdomen result in nausea and diarrhoea which usually respond to treatment. Proctitis, vaginal discharge and urinary problems all need attention. With cranial radiation, hair loss is a major problem and unlike chemotherapy induced alopecia, there is poor recovery. Patients must be informed that their condition will improve when radiation ceases, and not attribute all symptoms to underlying disease. Protection in this country is in line with international standards and strict adherence protects the work force. Patients with radioactive sources in situ e.g. radium or implants such as gold seeds, iridium wires, or being treated by radioactive iodine all require special nursing and are nursed in a protected ward. Staff wear film badges to detect radiation absorbed. If in doubt about safety measures contact superiors or radiophysics department of hospital. Patients already isolated from visitors must not be neglected and nurses must observe instructions and then proceed with safety.
 ...
PMID:About radiotherapy--Part II. Side effects and staff protection. 273 65

A comparative study of Norinyl 1/35 and Brevicon was conducted at the APLAFA clinic in Panama City, Panama. The study sought to evaluate the differences in continuation rates and the frequency of selected side effects which might contribute to method discontinuation. The 300 subjects were randomly allocated to one of the two oral contraceptives. Women in the Brevicon group reported significantly more (p less than 0.05) intermenstrual bleeding, nausea, headaches, dizziness and vaginal discharge than women in the Norinyl 1/35 group. The total discontinuation rate at 12 months was 28.0 for the Norinyl 1/35 group and 46.7 for the Brevicon group, and this difference was significant (p less than .01). Also, significantly more women (p less than .01) in the Brevicon group discontinued for menstrual problems than women in the Norinyl 1/35 group. No pregnancies were reported during this study. While both oral contraceptives appear safe and effective, Norinyl 1/35 was more acceptable to this group of Panamanian women.
 ...
PMID:A comparative study of Norinyl 1/35 versus Brevicon in Panama City, Panama. 344 38

4 reported cases of toxic shock syndrome (TSS) occurred in late 1983 among users of the vaginal contraceptive sponge (VCS). All patients manifested fever, hypotension, diffuse rash, desquamation, nausea, vomiting, myalgias, mucous membrane hyperemia, and vaginal discharge. All were hospitalized, treated with intravenous fluids and antimicrobial agents, and recovered. Vaginal cultures in each case were positive for Staphylococcus aureus. The VCS is made of polyurethane impregnated with the spermicide nonoxynol-9 and is intended to provide 24 hours of contraception. During clinical trials the average woman using only this method of contraception used 10 sponges/month. Package labels state that if symptoms compatible with TSS develop users should seek medical care. Women who use the VCS should read the package insert carefully and follow the manufacturer's directions. Women who have had TSS should consult a physician before using a VCS and so should postpartum women. If it is assumed that the 4 cases reported were attributable to a VCS, a minimum estimate of the incidence of nonmenstrual TSS associated with VCS use would be 10/year/100,000 women who use only VCS compared to 5-10/year/100,000 who use tampons. The use of contraceptive methods other than the VCS may also affect the risk of developing TSS; cases of nonemnstrual TSS among diaphragm users have been reported. Conversely the use of oral contraceptives may reduce the risk of developing menstrual TSS.
 ...
PMID:Toxic-shock syndrome and the vaginal contraceptive sponge. 631 70

Compilation of recent data on 1130 female volunteers from 17 US sites enrolled in a study of a new low dose combination oral contraceptive (OC) containing .15 mg levonorgestrel and .03 mg ethinyl estradiol are reported. All clients had complete histories and physical examinations at entrance and at 6 month intervals during treatment, and about 20% also had blood sugar, blood urea nitrogen, and liver profile determinations. Follow-up evaluation was performed after the 1st and 3rd cycles and every 3 cycles thereafter to determine patterns of pill taking, bleeding episodes, untoward effects, and concomitant medication. Clients ranged in age from 15-40 with mean age of 23.6; 76.1% were white, 11.9% black, 7.5% Hispanic, and 4.4% Oriental. 61.9% were of proven fertility and 92% had regular cycles. 48.1% of the study population had not used female hormones or been pregnant within 60 days of enrollment. A total of 11,064 cycles over a maximum 31 cycles of treatment are reported. Despite 1-6 or more missed pills in 1623, or 14.7% of the cycles, only 3 pregnancies were reported, only 1 presumed to be a method failure, for a use-effectiveness Pearl index of .35/100 women years of usage. Use of the formulation resulted in a mean cycle length of 28.5 days. 92.7% of cycles ranged from 26-30 days, almost equal to pretreatment values. The frequency of light menstrual flows increased. Breakthrough bleeding was reported in 669 cycles, or 6.0%, while spotting occurred in 852 cycles, or 7.7%. Amenorrhea was reported after 194 cycles (1.8%). No reports of post-pill amenorrhea were made. Incidence of side effects was very low. Only acne, breast discomfort, dysmenorrhea, gastrointestinal symptoms, headache, nausea, and vaginal discharge were reported in more than 1.0% of cycles. The pill had essentially no effect on weight or blood pressure, and produced no clinically significant laboratory abnormalities in hematology, urine, blood sugar, blood urea nitrogen, or liver profile determination. A total of 515 subjects (45.6%) discontinued use of the drug for various nonmedical reasons. Another 146 women (12.9%) discontinued use and gave medical reasons; 132, or 11.7%, were commonly reported side effects of OCs such as breakthrough bleeding, headache, and nausea. Clinical trials with the formulation have shown it to be a safe and effective ultra-low dose combined OC agent whose mode of action is primarily gonadotropin suppression and subsequent anovulation.
 ...
PMID:A new ultra-low-dose combination oral contraceptive. 640 5


1 2 3 Next >>